紫杉醇/顺铂(Paclitaxel/Cisplatin) - 药物靶点：DNA x Tubulin_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TP

靶点

DNA x Tubulin

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)、微管蛋白抑制剂、DNA烷化剂

+ [2]

治疗领域

肿瘤

在研适应症-

非在研适应症

局部晚期头颈部鳞状细胞癌

原研机构

天津市肿瘤研究所

在研机构-

非在研机构

天津市肿瘤研究所

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

查看全部结构式(2)

关联

12

项与紫杉醇/顺铂相关的临床试验

NCT06588335

/ Not yet recruiting临床2期IIT

A Single-Center, Exploratory Study of BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal squamous cell carcinoma that is resectable. The plan is to enroll 20 patients with locally advanced resectable thoracic esophageal cancer. In the neoadjuvant treatment phase, patients will receive JS004 + toripalimab + chemotherapy (paclitaxel + cisplatin) for 2 cycles. This will be followed by the surgical phase: surgery will be performed 3-8 weeks after the last dose of neoadjuvant treatment. In the postoperative maintenance treatment phase, maintenance treatment will start 4 weeks ± 7 days after surgery, but no later than 10 weeks after surgery. For patients with R0 resection confirmed by postoperative pathology, they will receive maintenance treatment with JS004 + toripalimab for up to 15 cycles. For patients with non-R0 resection, they will receive maintenance treatment with JS004 + toripalimab combined with standard radiation or chemotherapy (selected by the investigator based on esophageal cancer guidelines). During the study, the maximum number of cycles of JS004 combined with toripalimab is 17 cycles (approximately 1 year).

开始日期2024-09-30

申办/合作机构

河南省人民医院

NCT06444009

/ Recruiting临床2期IIT

Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II Study

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.
This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

开始日期2024-07-01

申办/合作机构

四川大学华西医院（四川省国际医院）

NCT05520619

/ Active, not recruiting临床2期IIT

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in EC. The aim of this study was to evaluate whether the efficacy of tislelizumab (an anti-PD-1 antibody) plus induction chemotherapy followed by concurrent chemoradiotherapy would achieve a ≥71% 1-year progression-free survival rate, surpassing the historical 56% rate (NCT02403531) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

开始日期2022-09-15

申办/合作机构

中山大学

[+2]

100 项与紫杉醇/顺铂相关的临床结果

登录后查看更多信息

100 项与紫杉醇/顺铂相关的转化医学

登录后查看更多信息

100 项与紫杉醇/顺铂相关的专利（医药）

登录后查看更多信息

2,088

项与紫杉醇/顺铂相关的文献（医药）

2025-03-01·Pesticide Biochemistry and Physiology

A comparative study of the controllable release and insecticidal efficacy for two typical carrier methods on diamide insecticide delivery system

Article

作者: Huang, Yucong ; Yang, Huiying ; Liu, Xingyu ; Liu, Bingrui ; Li, Yahui ; Li, Shaochen

Using nano/microcarriers of pesticides in sustainable pest management represents a promising strategy for enhancing pesticide efficiency while mitigating environmental harm. The reported pesticide loading methods include one-step self-assembly encapsulation and two-step absorption loading, but the controllable release and insecticidal efficacy of these two methods have been infrequently evaluated. Herein, the typical diamide insecticide cyantraniliprole (CTP) was employed as the model pesticide. A hydrogen bond-driven one-step self-assembly method and a chemical deposition method were utilized to fabricate highly dispersed polylactic acid (PLA) microspheres and calcium carbonate (CaCO₃) microspheres. The resulting CTP-loaded PLA microspheres (CTP-PLA MS) and CaCO₃ microspheres (CTP-CaCO₃ MS) both exhibited high adhesion, resistance to rain erosion, and insecticidal activity under laboratory conditions. However, the functional CTP-PLA MS demonstrated superior sustained pesticide release performance, higher pesticide loading capacity, and less application amount than that of CTP-CaCO₃ MS. At the same time, the acute toxicity of CTP-PLA MS exhibited slightly reduced acute toxicity to honeybees (Apis mellifera), signifying enhanced biocompatibility. Finally, the CTP-PLA MS maintained superior insecticidal efficacy than the normal CTP in controlling O. nubilalis at a low concentration. The present study represents a promising pesticide carrier as a highly efficient, eco-friendly agent for sustained management of O. nubilalis.

2025-03-01·Reproductive Toxicology

Hormonal mechanism and pathogenetic therapy of citalopram-induced infertility in female rats

Article

作者: Suleyman, Halis ; Gumusburun, Neset ; Bulut, Seval ; Mendil, Ali Sefa ; Suleyman, Bahadir ; Bakan, Nuri ; Delibasi, Ilhan Bahri ; Yilmaz, Betul Kalkan ; Altuner, Durdu ; Mammadov, Renad

Citalopram is a selective serotonin reuptake inhibitor (SSRI) and has been associated with reproductive dysfunction in women. In this study, the effects of citalopram on reproductive health in female rats were investigated. Albino Wistar rats was divided into six groups (each group/n=12): healthy (HG), citalopram (CTP), cabergoline (CBR), metyrapone (MTP), cabergoline+citalopram (CBR+CTP), and metyrapone+citalopram (MTP+CTP). Initially, cabergoline 0.1mg/kg and metyrapone 50mg/kg were administered orally. A dose of 10mg/kg of citalopram was given orally one hour later. For 30 days, the treatment protocol was applied once a day. Then, blood samples were taken from the tail veins of six rats from each group for prolactin and corticosterone analyses and ovaries were removed after euthanasia. The ovaries were examined for oxidants and antioxidants and histopathologically. During two months, the remaining animals were kept with male rats. The rats that did not deliver during this period were considered infertile. In terms of oxidants and antioxidants, there was no significant difference between the groups (p>0.05). In half of the female rats, citalopram caused infertility, increased levels of prolactin and corticosterone, and damaged the ovaries histopathologically (p<0.05). Cabergoline suppressed the elevation of prolactin by citalopram (p<0.001) but did not prevent infertility. In contrast, metyrapone significantly prevented the citalopram-induced increase in corticosterone, infertility, and tissue damage induced by citalopram (p<0.05). According to the results of our study, the preventive effect of drugs that suppress excessive corticosterone on citalopram-induced infertility in rats may be encouraging for further clinical studies.

2024-11-01·3 Biotech

Pharmacokinetic predictions of ROS-mediated targets and genotoxin combinations via multiple ligand simultaneous docking and ROS evaluation in vitro using HepG2 cell lines

Article

作者: Sri Snehaa, C. P. ; Issac, Praveen Kumar ; Sri Snehaa, C P ; Rajaguru, Palanisamy ; Pugalenthi, Velan

Although combination therapy is known for its high efficacy, reduced side effects and drug resistance, toxicity remains a major drawback. Some of the genes are likely to induce hepatotoxicity through ROS-mediated mechanisms when a drug is metabolized alone or in combination in the liver. To address this, we have developed a scientific approach to predict the toxicity of different genotoxin combinations and validate their interactions with various targets. The current study is an extensive study of our previous set of in vivo rat liver microarray data processed using R studio for their functional analysis. About five combinations of genotoxins such as CPT/ETP, CPT/CPL, ETP/CPL, CP/CPT and EES/CP along with their differential gene expression targeting Chemical carcinogenesis-ROS are chosen for this study. We aim to examine the binding affinity of different genotoxin combinations using in silico multiple ligand simultaneous docking (MLSD) and are then bio-evaluated for cytotoxicity in vitro using human hepatocellular carcinoma cell lines (HepG2) with the MTT assay. As a result, dose-response cytotoxicity with its strength of interactions and a significant variance in ROS levels in the treated cells is observed compared to their IC₅₀ values. Out of 5 combinations such as CPT/CPL, ETP/CPL and EES/CP are found not only to be significantly cytotoxic but also induce oxidative stress specifically above their IC₅₀ values with good and moderate binding interactions ensuring their toxicity. On the contrary, the safe combinations are found to be CTP/ETP and CP/CPT possibly with no and tolerable adverse effects standing as preliminary information for researchers in drug design and development.

100 项与紫杉醇/顺铂相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期头颈部鳞状细胞癌	临床2期	中国	天津市肿瘤研究所	2021-11-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2023	N/A	局部晚期头颈部鳞状细胞癌新辅助	21	Pembrolizumab plus TP	(繭觸遞憲積衊製鏇憲蓋) = 鹽廠壓窪蓋繭鏇遞淵簾糧繭糧鹽齋醖鏇鹹構蓋 (築選糧夢夢積壓衊鏇繭 ) 更多	-	2023-12-02
ESMO_ASIA2023	N/A	局部晚期头颈部鳞状细胞癌新辅助	21	Pembrolizumab plus DP	(繭觸遞憲積衊製鏇憲蓋) = 願襯鏇遞繭餘憲糧憲簾糧繭糧鹽齋醖鏇鹹構蓋 (築選糧夢夢積壓衊鏇繭 ) 更多	-	2023-12-02
ASCO2016	临床2期	复发性宫颈癌	65	Cisplatin-Paclitaxel regimen	(憲鬱鹽餘獵築餘鹽築簾) = 膚鏇製鬱獵廠鏇淵糧鑰壓艱壓遞衊廠繭選醖遞 (製糧獵獵廠糧選膚艱製 ) 更多	积极	2016-05-20
ASCO2015	N/A	局部晚期头颈部鳞状细胞癌	-	Paclitaxel 80 mg/m2 plus cisplatin 75 mg/m2	(獵壓構顧鏇廠網蓋簾繭) = 鹹製網襯簾憲製憲衊觸鏇繭築壓範壓窪夢齋廠 (鏇築壓蓋鹹觸糧網築鬱 ) 更多	-	2015-05-20
ASCO2014	N/A	阴茎鳞状细胞癌	41	Paclitaxel plus cisplatin	(壓鏇願網鑰獵構膚遞構) = 齋蓋壓製築觸壓築膚鹹鹽鏇網蓋範糧繭鹹襯製 (夢獵鹽獵築鏇積壓鑰鑰 ) 更多	-	2014-05-20
ASCO_GU2014	N/A	阴茎鳞状细胞癌辅助 \| 新辅助	47	Paclitaxel plus cisplatin and 5-fluorouracil (T-PF)	(顧壓觸顧艱衊壓餘鹹廠) = 積觸範願構觸餘觸範積觸鏇鑰鹹構積廠襯遞鹽 (襯範鹽鏇範願窪顧壓鑰 )	-	2014-02-01
WCLC2013	N/A	晚期鳞状细胞肺癌	32	Docetaxel/cisplatin chemotherapy and thoracic radiotherapy	(選鏇繭鹽廠夢齋艱艱襯) = 鑰廠獵膚壓衊齋網選糧簾願選淵窪壓選繭築窪 (築觸夢積夢遞網顧簾夢, 63 ~ 97) 更多	-	2013-10-29
ASCO2013	N/A	晚期食管鳞状细胞癌	133	Paclitaxel plus cisplatin	(廠壓築襯築壓範艱齋蓋) = 鬱蓋遞構艱蓋簾廠獵醖願獵蓋觸觸獵範齋獵蓋 (簾簾製衊願蓋獵選選繭, 5.68 ~ 8.32) 更多	-	2013-05-20
ASCO2013	N/A	局部晚期宫颈癌	47	Cisplatin, paclitaxel, and capecitabine	遞鬱願窪淵齋齋蓋築範(遞簾艱夢願選積糧願鹽) = 廠廠築憲餘齋膚齋醖餘築淵築餘膚繭鑰淵顧壓 (築窪壓餘餘構積願簾糧 ) 更多	-	2013-05-20
ASCO2011	N/A	转移性胃癌一线 \| 二线	75	Paclitaxel, cisplatin, and fluorouracil (PCF)	(簾構獵觸壓範獵淵構繭) = 鬱遞範鏇夢餘繭艱網齋選醖齋鏇淵簾壓廠鹹網 (鹽築選艱遞膚鏇鑰膚願 ) 更多	-	2011-05-20
ASCO2011	临床2期	非小细胞肺癌	-	Paclitaxel plus cisplatin	(範膚願窪糧醖獵齋醖襯) = 齋衊壓獵壓襯鏇壓醖網窪繭構鏇廠觸遞鑰築築 (糧壓糧鬱糧廠範蓋願鹹 ) 更多	积极	2011-05-20
ASCO2011	临床2期	非小细胞肺癌	-	Paclitaxel plus cisplatin with Cadi-05	(範膚願窪糧醖獵齋醖襯) = 積遞網構願鏇範選鬱願窪繭構鏇廠觸遞鑰築築 (糧壓糧鬱糧廠範蓋願鹹 ) 更多	积极	2011-05-20